Non-Hydroxamate Inhibitors of IspC Enzyme in the MEP Pathway: Structural Insights and Drug Development Potential
Yaqing Zhou1, Jili Wang1, Yong Sun1
1Shiyan Key Laboratory of Biological Resources and eco-Environmental Protection, College of Chemical and Environmental Engineering, Hanjiang Normal University, Shiyan, China.
Abstract:
1-Deoxy-D-xylulose-5-phosphate reductoisomerase (IspC) is a key enzyme in the MEP pathway, essential for many bacteria, human pathogens, and plants, thus being an attractive drug target. Fosmidomycin, a potent IspC inhibitor with hydroxamate metal-binding pharmacophores (MBPs), has entered clinical trials for malaria but is hampered by pharmacokinetic and toxicity issues of the hydroxamate fragment. This has led to increased interest in non-hydroxamate inhibitors. This review focuses on the crystal structure and active-site binding mode of IspC, and the structural types, inhibitory activities, and structure-activity relationships of non-hydroxamate IspC inhibitors. Early attempts to design such inhibitors involved direct removal or replacement of the hydroxamate MBPs, with varying results. Lipophilic inhibitors, bisubstrate inhibitors, and those developed for herbicidal applications have shown promise. However, challenges remain due to the sensitivity of the enzyme active site to ligand interactions. Future research could draw from other metalloenzyme studies to develop novel and efficient non-hydroxamate IspC inhibitors.
Insights
Non-hydroxamate inhibitors targeting 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (IspC) are crucial for developing new drugs. Research explores their structures and activity, aiming to overcome limitations of current hydroxamate-based inhibitors.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Enzymology
Background:
- 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (IspC) is vital for the MEP pathway in bacteria, pathogens, and plants, making it a key drug target.
- Fosmidomycin, a hydroxamate-based IspC inhibitor, shows potential but faces pharmacokinetic and toxicity challenges.
- The limitations of hydroxamate inhibitors necessitate the development of alternative non-hydroxamate compounds.
Purpose of the Study:
- To review the crystal structure and active-site binding of IspC.
- To analyze the structural diversity, inhibitory activity, and structure-activity relationships of non-hydroxamate IspC inhibitors.
- To identify future research directions for novel non-hydroxamate IspC inhibitors.
Main Methods:
- Literature review focusing on IspC structure and non-hydroxamate inhibitors.
- Analysis of crystal structures and active-site binding modes.
- Evaluation of inhibitory activities and structure-activity relationships (SAR).
Main Results:
- Non-hydroxamate inhibitors have been explored through modifications of existing hydroxamate structures.
- Promising results observed with lipophilic inhibitors, bisubstrate inhibitors, and compounds developed for herbicidal applications.
- Challenges persist due to the enzyme's active site sensitivity to ligand interactions.
Conclusions:
- Developing effective non-hydroxamate IspC inhibitors requires careful consideration of enzyme-ligand interactions.
- Further research, potentially drawing from metalloenzyme studies, is needed to create novel and efficient inhibitors.
- Non-hydroxamate inhibitors offer a promising avenue for overcoming the limitations of current IspC-targeting drugs.
Related Concept Videos
01:30Enzyme Inhibition
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
01:29Pharmacogenomics: Identification of New Drug Targets
01:23Dipeptidyl Peptidase 4 Inhibitors